All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: An expert panel position paper

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00060030" target="_blank" >RIV/00023001:_____/16:00060030 - isvavai.cz</a>

  • Result on the web

    <a href="http://www.sciencedirect.com/science/article/pii/S0167527316315972" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0167527316315972</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.ijcard.2016.07.202" target="_blank" >10.1016/j.ijcard.2016.07.202</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: An expert panel position paper

  • Original language description

    Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompensated heart failure (HF) patients with low cardiac output. Accumulated evidence supports several pleiotropic effects of levosimendan beyond inotropy, the heart and decompensated HF. Those effects are not readily explained by cardiac function enhancement and seem to be related to additional properties of the drug such as anti-inflammatory, anti-oxidative and anti-apoptotic ones. Mechanistic and proof-of-concept studies are still required to clarify the underlying mechanisms involved, while properly designed clinical trials are warranted to translate preclinical or early-phase clinical data into more robust clinical evidence. The present position paper, derived by a panel of 35 experts in the field of cardiology, cardiac anesthesiology, intensive care medicine, cardiac physiology, and cardiovascular pharmacology from 22 European countries, compiles the existing evidence on the pleiotropic effects of levosimendan, identifies potential novel areas of clinical application and defines the corresponding gaps in evidence and the required research efforts to address those gaps. (C) 2016 The Authors. Published by Elsevier Ireland Ltd.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    International journal of cardiology

  • ISSN

    0167-5273

  • e-ISSN

  • Volume of the periodical

    222

  • Issue of the periodical within the volume

    1 November

  • Country of publishing house

    IE - IRELAND

  • Number of pages

    10

  • Pages from-to

    303-312

  • UT code for WoS article

    000384698300056

  • EID of the result in the Scopus database